---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002599"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:52:25.280744+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fennec Pharma reports FY2024 PEDMARK sales $29.6M (+40% YoY); Q4 EBITDA loss $0.6M, cash $26.6M

## Summary
- FY2024 net product sales $29.6M, up 40% from $21.3M in 2023; net loss narrowed to $0.07M from $16.0M.
- Q4 2024 product sales $7.9M (+13% QoQ); EBITDA loss $0.6M; cash $26.6M at Dec 31, 2024.
- Early repaid $13M of ~$32M convertible debt, saving ~$1.5M annual interest; reduces potential dilution.
- Full-year operating income $2.6M vs loss $12.8M in 2023; G&A declined QoQ after one-time CEO severance.
- PEDMARQSI launched in UK and Germany; Japan trial results (STS-J01) expected H2 2025.

## SEC filing metadata
- accession: 0001558370-25-002599
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/0001558370-25-002599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/fencf-20250310x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002599
- JSON: https://secwatch.observer/filing/0001558370-25-002599.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.